May 18, 2012
Pfizer Japan resubmitted a new drug application (NDA) for the overactive bladder treatment fesoterodine fumarate (development code: SPM8272) to the Ministry of Health, Labor and Welfare (MHLW) in March. It was disclosed in a financial report submitted by its parent...read more